rifanmuazin
Andrew Engdahl, the Head of Sales at the leading post-click automation platform Instapage, has been officially nominated as a candidate for the Leukemia & Lymphoma Society’s (LLS) Visionaries of the Year campaign. This prestigious philanthropic competition recognizes influential community leaders who leverage their professional platforms to raise significant funds and awareness for the fight against blood cancers. Engdahl’s nomination follows his remarkable personal triumph over Stage 4 Non-Hodgkin’s Lymphoma, a diagnosis that he received in 2022 and which has since informed his mission to support others navigating similar life-threatening medical crises. By setting a fundraising goal of $50,000, Engdahl aims to contribute directly to the research and patient support services that were instrumental in his own recovery.
A Life-Altering Diagnosis and the Path to Recovery
The narrative of Andrew Engdahl’s campaign is inextricably linked to a harrowing medical journey that began in the summer of 2022. At the time, Engdahl was a high-performing executive at Instapage, balancing the demands of a competitive technology sales environment. What initially presented as routine muscle tension—a common complaint for professionals spending long hours at a desk—rapidly escalated into a debilitating health crisis. Within a short period, diagnostic testing revealed the presence of Stage 4 Non-Hodgkin’s Lymphoma (NHL), a cancer that originates in the lymphatic system and, in its fourth stage, indicates that the disease has spread to organs outside the lymph nodes, such as the liver, lungs, or bone marrow.
The aggressive nature of the diagnosis required an equally aggressive treatment regimen. Engdahl’s clinical path was marked by high-stakes interventions, including major spinal surgery to address complications arising from the cancer’s progression. This was followed by a grueling series of treatments: four lumbar punctures—procedures involving the insertion of a needle into the spinal canal to collect or inject fluid—and six intensive chemotherapy infusions. These treatments, while necessary to eradicate the malignant cells, often cause severe physical and cognitive fatigue.
Beyond the clinical interventions, Engdahl’s recovery required a rigorous six-month period of physical therapy and yoga. This holistic approach to rehabilitation was essential for regaining the mobility and strength lost during the surgery and subsequent chemical treatments. Today, Engdahl has been in remission for nearly three years, a milestone that underscores the efficacy of modern hematological treatments and the resilience of the human spirit.
Understanding Non-Hodgkin’s Lymphoma: The Clinical Context
To understand the weight of Engdahl’s journey, it is necessary to examine the broader context of Non-Hodgkin’s Lymphoma. According to data from the American Cancer Society, NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. The disease involves the abnormal growth of lymphocytes, a type of white blood cell that is part of the body’s immune system.
In 2024 alone, it is estimated that approximately 80,620 people will be diagnosed with NHL. While the overall five-year relative survival rate for NHL is approximately 74%, the prognosis varies significantly based on the subtype and the stage at the time of diagnosis. For Stage 4 patients, the journey is traditionally more complex, requiring the multidisciplinary approach that Engdahl experienced. Advances in immunotherapy, targeted therapy, and refined chemotherapy protocols have significantly improved outcomes for late-stage patients over the last decade. The Leukemia & Lymphoma Society has been a primary driver of this progress, investing more than $1.7 billion in research since its inception in 1949.
The Visionaries of the Year Campaign: A Platform for Change
The Visionaries of the Year campaign (formerly known as Man & Woman of the Year) is a signature 10-week philanthropic competition hosted by the Leukemia & Lymphoma Society. Candidates are selected based on their leadership, community involvement, and ability to mobilize networks for a common cause. Every dollar raised counts as one "vote," and the candidates who raise the most funds in their respective communities are named the Visionaries of the Year.
Engdahl officially launched his campaign on World Cancer Day, a global initiative led by the Union for International Cancer Control (UICC). By aligning his announcement with this international day of awareness, Engdahl emphasized the collective nature of the fight against cancer. His $50,000 fundraising goal is designed to support the LLS mission on three fronts:
- Research: Funding the next generation of blood cancer treatments, including CAR-T cell therapy and precision medicine.
- Patient Support: Providing financial assistance, educational resources, and support groups for patients and their families.
- Advocacy: Working at the state and federal levels to ensure patients have access to affordable, high-quality care.
Engdahl has articulated that his motivation is rooted in a sense of "paying it forward." Having benefited from the medical breakthroughs funded by previous generations of donors, he views his current health and professional success as a mandate to act. "I feel that I owe it to my physicians, my friends, family, and teammates, and all those affected by the scourge of blood cancer to pay it forward and make a difference while I still have the strength and ability to do so," Engdahl stated during his campaign kickoff.
Corporate Leadership and Professional Resilience
The role of a Head of Sales at a high-growth technology company like Instapage is inherently demanding. It requires strategic foresight, the ability to manage high-pressure deal cycles, and the leadership to guide a global team toward ambitious revenue targets. Engdahl’s ability to transition from a Stage 4 cancer patient back into a top-tier executive role is a testament to his resilience and the supportive culture of his organization.
Instapage has publicly championed Engdahl’s efforts, noting that he has been instrumental in closing some of the company’s largest enterprise deals even as he navigated his recovery. The company’s leadership team has highlighted his "joy and optimism" as defining characteristics that influence the workplace culture. In a professional landscape where "burnout" is a common topic of discussion, Engdahl’s perspective offers a unique counter-narrative: that professional ambition can coexist with, and even be fueled by, a profound appreciation for life’s fragility.
The intersection of corporate leadership and philanthropy is a growing trend in the modern business world. Companies are increasingly looking for leaders who embody "servant leadership"—the idea that the most effective leaders are those who serve their communities and teams. Engdahl’s campaign serves as a case study in how individual personal experiences can be transformed into corporate social responsibility (CSR) initiatives that resonate with employees and clients alike.
Broader Implications for the Tech Industry and Philanthropy
Engdahl’s story highlights a critical intersection between the technology sector and health advocacy. As the tech industry continues to dominate the economic landscape, the influence of its leaders extends beyond software and innovation. When executives like Engdahl use their visibility to highlight health crises, it brings a level of awareness and capital to medical causes that might otherwise struggle for attention.
Furthermore, the "Visionaries of the Year" campaign demonstrates the power of peer-to-peer fundraising in the digital age. By utilizing social networks, professional platforms like LinkedIn, and corporate partnerships, candidates can mobilize large-scale support rapidly. This model of philanthropy is particularly effective in the tech industry, where networking and digital engagement are core competencies.
The impact of such campaigns is measurable. Funds raised through LLS initiatives have contributed to the FDA approval of 85% of all blood cancer treatments since 2017. For patients like Engdahl, these statistics are not just numbers; they represent the difference between a terminal prognosis and a second chance at life.
A Timeline of Resilience
To fully grasp the scope of Engdahl’s journey, a look at the chronology of events provides essential context:
- Summer 2022: Engdahl experiences initial symptoms, initially dismissed as muscle tension.
- Late 2022: Formal diagnosis of Stage 4 Non-Hodgkin’s Lymphoma; immediate commencement of spinal surgery and chemotherapy.
- 2023: A grueling year of rehabilitation, including four lumbar punctures and intensive physical therapy, while maintaining his role at Instapage.
- 2024: Reaching a milestone of two years in remission; Engdahl is promoted to Head of Sales, leading global sales initiatives.
- February 4, 2025: On World Cancer Day, Engdahl officially announces his candidacy for LLS Visionaries of the Year.
- Present: The campaign continues with a goal to reach $50,000 through community and corporate donations.
Official Responses and Community Support
The response from the Instapage community and the broader tech sector has been one of overwhelming support. Colleagues have noted that Engdahl’s openness about his struggle has fostered a more empathetic and transparent environment within the sales team. Industry analysts suggest that this type of "vulnerable leadership" can lead to higher employee retention and morale, as it humanizes the executive tier.
Representatives from the Leukemia & Lymphoma Society have also expressed their gratitude for Engdahl’s participation. An LLS spokesperson noted that candidates like Engdahl are vital because they provide a "face" to the cause, making the abstract need for research funding tangible through their personal survival stories.
Conclusion: The Path Forward
As Andrew Engdahl’s campaign moves forward, it stands as a beacon of hope for those currently in the midst of their own battles with blood cancer. His story is a reminder that a diagnosis—even one as severe as Stage 4 Lymphoma—does not necessarily signal the end of a career or a meaningful life. Instead, it can serve as a catalyst for a new chapter defined by purpose, advocacy, and a commitment to ensuring that future patients have access to the same life-saving treatments that he received.
Through his work at Instapage and his leadership in the Visionaries of the Year campaign, Engdahl is demonstrating that true leadership is measured not just by revenue growth, but by the impact one has on the lives of others. The $50,000 goal, while ambitious, represents a vital contribution to a future where blood cancer is no longer a life-threatening reality. For those interested in supporting this cause, donations can be made directly through the official LLS campaign page, contributing to a legacy of research and resilience.
